Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
BUSINESS
Orion to Take Over Divigel as Its 1st Product in Japan
Finnish drug maker Orion is succeeding the Japanese marketing authorization for the transdermal gel estrogen therapy Divigel (estradiol) from Sun Pharma, effective October 31, making it the company’s first commercial product in Japan. The transfer was announced on October 2…
To read the full story
Related Article
- Orion Now MA Holder of Parkinson’s Meds Stalevo, Comtan in Japan
December 24, 2024
- Orion Starts Sales of Divigel as Its 1st Product in Japan
November 6, 2024
- Orion Japan to Take Back Parkinson’s Drugs from Novartis
October 31, 2024
- Finnish Pharma Orion Poised for Japan Debut with Reacquisition of Parkinson’s Meds This Year
June 26, 2024
BUSINESS
- Pfizer to Donate RSV Jabs to 12 Municipalities in Noto Peninsula
April 22, 2025
- Ono Links Arms with Jorna on RNA Editing Therapeutics
April 22, 2025
- Novo Partners with Asahikawa City on Obesity Measures
April 22, 2025
- Enhertu Hits Mark in 1st Line Breast Cancer with PIII Trial Win
April 22, 2025
- Effexor Filed for Generalized Anxiety Disorder in Japan: Viatris
April 22, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…